Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. scores highest on Earnings (81) and lowest on Price (48). Its PosiPenta is 64.57 out of 100, better than most similar companies.
On the Penta Grid this week, Neurocrine Biosciences, Inc. is Grid #67 of 837 in the Healthcare sector in United States, and Grid #242 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. | 64.57 | 48 | 81 | 62 | 70 | 62 |
| Solventum Corporation | 67.03 | 62 | 57 | 90 | 55 | 71 |
| Halozyme Therapeutics, Inc. | 62.50 | 17 | 91 | 99 | 50 | 55 |
| BridgeBio Pharma, Inc. | 53.98 | 0 | 48 | 67 | 96 | 60 |
| Baxter International Inc. | 56.40 | 28 | 62 | 84 | 41 | 67 |
| Exelixis, Inc. | 68.50 | 39 | 68 | 98 | 74 | 63 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | 19.90 |
| P/B ratio | 3.73 |
EEarnings
| Trailing EPS | ₹645.96 |
| Forward EPS | ₹1131.89 |
NNitro
| Price | 12853.77 |
| 52-week high | 17628.35 |
| 52-week low | 11568.48 |
| Fall from 52-week high | 27.1% |
TTorque
| Return on equity (ROE) | 22.09% |
| Debt-to-equity | 0.12 |
AAnchor
| Beta (price swings) | 0.40 |
| Market cap | ₹1,30,657 Cr |
| Insider holding | 1.06% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Neurocrine Biosciences, Inc.'s PosiPenta score?
Neurocrine Biosciences, Inc.'s PosiPenta is 64.57 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Neurocrine Biosciences, Inc. stand on the Penta Grid?
On the Penta Grid this week, Neurocrine Biosciences, Inc. is Grid #67 of 837 in the Healthcare sector in United States, and Grid #242 of 4,000 in United States.
Which PosiPenta pillar is strongest for Neurocrine Biosciences, Inc.?
Earnings (growth), with a score of 81 out of 100: much better than most similar companies.
Which PosiPenta pillar is weakest for Neurocrine Biosciences, Inc.?
Price (valuation), with a score of 48 out of 100: around the middle of similar companies.
Has Neurocrine Biosciences, Inc.'s PosiPenta changed since last week?
Yes, it rose 8.39 points, from 56.18 to 64.57.
PositoAI is for research and education only and is not investment advice.